Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16

Author: Benzinga Newsdesk | April 10, 2025 05:48am
HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics (NASDAQ:TPST) from Buy to Neutral and maintains the price target from $16 to $16.

Posted In: TPST


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist